Trading Signals: AUTL Stock Price Prediction and Forecast (Fri. Jun. 22, 2018 - Fri. May. 13, 2022)(Autolus Therapeutics plc )
| AUTL latest price $4.4100 (0.57%) ($4.4100 - $4.4100) on Fri. Jan. 14, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 5.03% (three month average) | RSI | 29 | Latest Price | $4.4100(0.57%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | AUTL declines -1.1% a day on average for past five trading days. | Weekly Trend | AUTL declines -6.9% a week on average for past two weeks. | Market Behavior | Normal for large cap. Value stock rally for small cap. | Correlated ETFs | Broad market will support AUTL advance at 0% a week (0% probability) XBI(65%) IBB(61%) IBUY(57%) ARKG(55%) ARKK(54%) | Factors Impacting AUTL price | AUTL will decline at least -2.515% in a week (0% probabilities). VIXM(-43%) VXX(-34%) TLT(-23%) SHY(-21%) TIP(-20%) | | | | | Relative Volatility | | | | Market Trend Strength | -2.515% (StdDev 5.03%) | Hourly BBV | -0.6 () | Intraday Trend | 0% | | | |
|
1 - 5 Day Possible Target | $-8.7(-297.28%) | Resistance Level | $5.03 | 5 Day Moving Average | $4.56(-3.29%) | 10 Day Moving Average | $4.77(-7.55%) | 20 Day Moving Average | $5.03(-12.33%) | To recent high | -37.4% | To recent low | 0.6% | Market Cap | $230m | | | | Autolus Therapeutics Plc is a biopharmaceutical company. It engages in the development of cancer treatments. The firm's portfolio includes B Cell Malignancies, Multiple Myeloma, T Cell Lymphoma, GD2+ Tumors, and Prostate Cancer. The company was founded by Martin Pulé in February 2018 and is headquartered in London, the United Kingdom. |